Peter F Thall1, Richard C Herrick2, Hoang Q Nguyen2, John J Venier2, J Clift Norris2. 1. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA rex@mdanderson.org. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: The efficacy-toxicity trade-off based design is a practical Bayesian phase I-II dose-finding methodology. Because the design's performance is very sensitive to prior hyperparameters and the shape of the target trade-off contour, specifying these two design elements properly is essential. PURPOSE: The goals are to provide a method that uses elicited mean outcome probabilities to derive a prior that is neither overly informative nor overly disperse, and practical guidelines for specifying the target trade-off contour. METHODS: A general algorithm is presented that determines prior hyperparameters using least squares penalized by effective sample size. Guidelines for specifying the trade-off contour are provided. These methods are illustrated by a clinical trial in advanced prostate cancer. A new version of the efficacy-toxicity program is provided for implementation. RESULTS: Together, the algorithm and guidelines provide substantive improvements in the design's operating characteristics. LIMITATIONS: The method requires a substantial number of elicited values and design parameters, and computer simulations are required to obtain an acceptable design. CONCLUSION: The two key improvements greatly enhance the efficacy-toxicity design's practical usefulness and are straightforward to implement using the updated computer program. The algorithm for determining prior hyperparameters to ensure a specified level of informativeness is general, and may be applied to models other than that underlying the efficacy-toxicity method.
BACKGROUND: The efficacy-toxicity trade-off based design is a practical Bayesian phase I-II dose-finding methodology. Because the design's performance is very sensitive to prior hyperparameters and the shape of the target trade-off contour, specifying these two design elements properly is essential. PURPOSE: The goals are to provide a method that uses elicited mean outcome probabilities to derive a prior that is neither overly informative nor overly disperse, and practical guidelines for specifying the target trade-off contour. METHODS: A general algorithm is presented that determines prior hyperparameters using least squares penalized by effective sample size. Guidelines for specifying the trade-off contour are provided. These methods are illustrated by a clinical trial in advanced prostate cancer. A new version of the efficacy-toxicity program is provided for implementation. RESULTS: Together, the algorithm and guidelines provide substantive improvements in the design's operating characteristics. LIMITATIONS: The method requires a substantial number of elicited values and design parameters, and computer simulations are required to obtain an acceptable design. CONCLUSION: The two key improvements greatly enhance the efficacy-toxicity design's practical usefulness and are straightforward to implement using the updated computer program. The algorithm for determining prior hyperparameters to ensure a specified level of informativeness is general, and may be applied to models other than that underlying the efficacy-toxicity method.